Methods of modifying insulin signaling using biliverdin reductase
AssigneeUniversity of Rochester
InventorMahin D. Maines
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of modulating insulin signaling in a cell. This method involves modifying the nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, in a cell, whereby a change in nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, modulates insulin signaling in the cell via biliverdin reductase interaction with one or both of insulin receptor kinase domain and insulin receptor substrate. Also disclosed are methods of treating a condition associated with insulin signaling and treating a patient for a condition associated with insulin-mediated glucose uptake.
Claims32
A method of modulating insulin signaling in a cell, said method comprising:
- modifying the nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, in a cell, whereby a change in nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, modulates insulin signaling in the cell via biliverdin reductase interaction with one or both of insulin receptor kinase domain and insulin receptor substrate.
A method of treating a patient for a condition associated with insulin-mediated glucose uptake, said method comprising:
- administering to a patient having a condition associated with insulin-mediated glucose uptake an effective amount of a nucleic acid that inhibits native biliverdin reductase expression or activity,
- wherein decreased native biliverdin reductase expression or activity promotes insulin-mediated glucose uptake by cells, and effectively treats a condition associated with insulin-mediated glucose uptake.
32-36. (canceled)
Dependencies are inferred from the claim text.